GU Cancers 2024 | Real-world insights of ARSIs and ADTs in mCSPC

Benjamin Maughan, MD, PharmD, University of Utah, Salt Lake City, UT, discusses the role of androgen receptor signaling inhibitors (ARSI) with androgen deprivation therapy (ADT) in the real-world setting for metastatic castration-sensitive prostate cancer (mCSPC). Results from an observational cohort study demonstrated the superior efficacy of apalutamide and ADT over other ARSIs, docetaxel with ADT, and ADT alone. Patients initiating apalutamide with ADT demonstrated higher rates of PSA response and prolonged castration resistance (CR)-free survival. This interview took place at the ASCO GU Cancers Symposium 2024 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.